Youthful Cream is a prescription therapy used for skin hydration and firmness support.

Patients seeking support for skin hydration and firmness support may qualify after evaluation by a licensed provider.

Yes. Youthful Cream is a compounded prescription topical medication containing tretinoin (teratogenic retinoid), estriol (topical estrogen), and finasteride (5-alpha reductase inhibitor), all of which require a valid prescription from a licensed healthcare provider. A telehealth consultation, full medical intake, and thorough patient counseling are required before dispensing.

Tretinoin-related adjustment effects during the initial 2 to 4 weeks include redness, peeling, and dryness, meaningfully reduced by niacinamide's tolerability buffering. Increased UV sensitivity requires mandatory daily SPF. Estriol may rarely cause mild systemic estrogenic effects (breast tenderness) with significant absorption. Topical finasteride at facial compounding concentrations is not expected to cause the sexual side effects associated with systemic oral finasteride in men; however, any unexpected hormonal symptoms should be reported to your provider. Wash hands thoroughly after application; finasteride can be absorbed through the skin of others who handle the product.

Absolutely contraindicated in pregnancy and in women who may become pregnant, both tretinoin and finasteride are teratogenic; this product must never be handled by pregnant women. Reliable contraception is required throughout treatment. Not appropriate during breastfeeding. Patients with a personal history of hormone-sensitive malignancies (estrogen receptor-positive breast or endometrial cancer, hormone-sensitive prostate conditions) must discuss use with their oncologist before initiating. Known retinoid, finasteride, estriol, or niacinamide hypersensitivities are contraindications. Do not apply to actively inflamed, sunburned, or eczematous skin.

Other topical retinoids must not be combined: doing so increases irritation dramatically. Benzoyl peroxide inactivates tretinoin on direct contact. AHAs and BHAs increase barrier disruption during the retinoid adjustment period. Patients on systemic menopausal HRT, oral contraceptives, or systemic finasteride or dutasteride should ensure all providers are aware of the estriol and finasteride components of this formula. High-dose zinc supplementation or copper-chelating topicals should be discussed with your provider. Photosensitizing medications require vigilant daily SPF adherence.

Patients with a history of hormone-sensitive malignancy, including estrogen receptor-positive breast cancer, endometrial cancer, or hormone-sensitive prostate conditions, must obtain oncological clearance before initiating. Active inflammatory skin conditions must be stable before beginning therapy. Patients with known coagulation disorders should discuss finasteride's androgen-modulating activity with their provider. Regular provider follow-up is standard of care throughout treatment. Your provider will conduct a thorough medical and dermatological review before prescribing.